Management of patients after cardiac transplantation

L. J. Olson, R. J. Rodeheffer

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

During the past decade, the morbidity and mortality associated with cardiac transplantation have decreased dramatically. The current survival for patients who undergo orthotopic cardiac transplantation is 80 to 90% at 1 year and 70 to 80% at 5 years; these results are attributed chiefly to improved immunosuppression and the consequent decrease in infectious illnesses and rejection. Because surgical mortality and technique have not changed appreciably during the past 20 years, improved survival can be ascribed to advances in the medical management of recipients of cardiac transplants. Medical problems frequently encountered in such patients include allograft rejection, allograft vasculopathy, hypertension, renal dysfunction, hyperlipidemia, hyperglycemia, malignant disorders, general surgical disease, and osteopenic bone disease. Hence, the expertise needed for management of patients who undergo cardiac transplantation is not confined to a particular specialty-optimal care necessitates the integrated efforts of a team, including transplant physicians and personnel to provide broad subspecialty and laboratory support. Meticulous management with proactive intervention and minimal effective immunosuppression will prevent or ameliorate many problems and contribute to increased survivorship and improved quality of life. For additional substantive improvement in long-term survival and quality of life for recipients of cardiac allografts, multicenter, prospective, and placebo- controlled clinical investigations will be necessary.

Original languageEnglish (US)
Pages (from-to)775-784
Number of pages10
JournalMayo Clinic Proceedings
Volume67
Issue number8
StatePublished - 1992

Fingerprint

Heart Transplantation
Allografts
Immunosuppression
Survival
Quality of Life
Renal Hypertension
Mortality
Bone Diseases
Hyperlipidemias
Hyperglycemia
Survival Rate
Placebos
Morbidity
Physicians
Transplants

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Olson, L. J., & Rodeheffer, R. J. (1992). Management of patients after cardiac transplantation. Mayo Clinic Proceedings, 67(8), 775-784.

Management of patients after cardiac transplantation. / Olson, L. J.; Rodeheffer, R. J.

In: Mayo Clinic Proceedings, Vol. 67, No. 8, 1992, p. 775-784.

Research output: Contribution to journalArticle

Olson, LJ & Rodeheffer, RJ 1992, 'Management of patients after cardiac transplantation', Mayo Clinic Proceedings, vol. 67, no. 8, pp. 775-784.
Olson, L. J. ; Rodeheffer, R. J. / Management of patients after cardiac transplantation. In: Mayo Clinic Proceedings. 1992 ; Vol. 67, No. 8. pp. 775-784.
@article{d3a59d7846bf4c88ac1844ed72ca9fa1,
title = "Management of patients after cardiac transplantation",
abstract = "During the past decade, the morbidity and mortality associated with cardiac transplantation have decreased dramatically. The current survival for patients who undergo orthotopic cardiac transplantation is 80 to 90{\%} at 1 year and 70 to 80{\%} at 5 years; these results are attributed chiefly to improved immunosuppression and the consequent decrease in infectious illnesses and rejection. Because surgical mortality and technique have not changed appreciably during the past 20 years, improved survival can be ascribed to advances in the medical management of recipients of cardiac transplants. Medical problems frequently encountered in such patients include allograft rejection, allograft vasculopathy, hypertension, renal dysfunction, hyperlipidemia, hyperglycemia, malignant disorders, general surgical disease, and osteopenic bone disease. Hence, the expertise needed for management of patients who undergo cardiac transplantation is not confined to a particular specialty-optimal care necessitates the integrated efforts of a team, including transplant physicians and personnel to provide broad subspecialty and laboratory support. Meticulous management with proactive intervention and minimal effective immunosuppression will prevent or ameliorate many problems and contribute to increased survivorship and improved quality of life. For additional substantive improvement in long-term survival and quality of life for recipients of cardiac allografts, multicenter, prospective, and placebo- controlled clinical investigations will be necessary.",
author = "Olson, {L. J.} and Rodeheffer, {R. J.}",
year = "1992",
language = "English (US)",
volume = "67",
pages = "775--784",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Management of patients after cardiac transplantation

AU - Olson, L. J.

AU - Rodeheffer, R. J.

PY - 1992

Y1 - 1992

N2 - During the past decade, the morbidity and mortality associated with cardiac transplantation have decreased dramatically. The current survival for patients who undergo orthotopic cardiac transplantation is 80 to 90% at 1 year and 70 to 80% at 5 years; these results are attributed chiefly to improved immunosuppression and the consequent decrease in infectious illnesses and rejection. Because surgical mortality and technique have not changed appreciably during the past 20 years, improved survival can be ascribed to advances in the medical management of recipients of cardiac transplants. Medical problems frequently encountered in such patients include allograft rejection, allograft vasculopathy, hypertension, renal dysfunction, hyperlipidemia, hyperglycemia, malignant disorders, general surgical disease, and osteopenic bone disease. Hence, the expertise needed for management of patients who undergo cardiac transplantation is not confined to a particular specialty-optimal care necessitates the integrated efforts of a team, including transplant physicians and personnel to provide broad subspecialty and laboratory support. Meticulous management with proactive intervention and minimal effective immunosuppression will prevent or ameliorate many problems and contribute to increased survivorship and improved quality of life. For additional substantive improvement in long-term survival and quality of life for recipients of cardiac allografts, multicenter, prospective, and placebo- controlled clinical investigations will be necessary.

AB - During the past decade, the morbidity and mortality associated with cardiac transplantation have decreased dramatically. The current survival for patients who undergo orthotopic cardiac transplantation is 80 to 90% at 1 year and 70 to 80% at 5 years; these results are attributed chiefly to improved immunosuppression and the consequent decrease in infectious illnesses and rejection. Because surgical mortality and technique have not changed appreciably during the past 20 years, improved survival can be ascribed to advances in the medical management of recipients of cardiac transplants. Medical problems frequently encountered in such patients include allograft rejection, allograft vasculopathy, hypertension, renal dysfunction, hyperlipidemia, hyperglycemia, malignant disorders, general surgical disease, and osteopenic bone disease. Hence, the expertise needed for management of patients who undergo cardiac transplantation is not confined to a particular specialty-optimal care necessitates the integrated efforts of a team, including transplant physicians and personnel to provide broad subspecialty and laboratory support. Meticulous management with proactive intervention and minimal effective immunosuppression will prevent or ameliorate many problems and contribute to increased survivorship and improved quality of life. For additional substantive improvement in long-term survival and quality of life for recipients of cardiac allografts, multicenter, prospective, and placebo- controlled clinical investigations will be necessary.

UR - http://www.scopus.com/inward/record.url?scp=0026769478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026769478&partnerID=8YFLogxK

M3 - Article

C2 - 1434917

AN - SCOPUS:0026769478

VL - 67

SP - 775

EP - 784

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -